会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Method for administering an NMDA receptor antagonist to a subject
    • 给受试者施用NMDA受体拮抗剂的方法
    • US08598233B2
    • 2013-12-03
    • US13751876
    • 2013-01-28
    • Adamas Pharmaceuticals, Inc.
    • Gregory T. WentTimothy J. FultzLaurence R. Meyerson
    • A61K9/00A61K31/17A01N47/28
    • A61K31/13A61K9/4891Y10S514/964
    • Compositions and methods for administering memantine to a subject are provided. In particular, a solid pharmaceutical composition in a unit dosage form for once daily oral administration is provided. The compositions comprises an extended release formulation of 22.5 mg to 33.75 mg memantine, or a pharmaceutically acceptable salt thereof, wherein administration of a dose of the composition to a human subject provides a mean plasma memantine concentration profile characterized by a change in memantine concentration as a function of time (dC/dT) that is less than 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours to 6 hours after administration of memantine, and wherein dC/dT is measured in a single-dose human PK study. Methods of treating dementia, in particular Alzheimer's diseases, using the compositions are provided.
    • 提供了向受试者施用美金刚的组合物和方法。 特别地,提供了一次每日口服给药的单位剂型的固体药物组合物。 组合物包含22.5mg至33.75mg美金刚或其药学上可接受的盐的延长释放制剂,其中向人受试者施用该剂量的组合物提供了以美金刚浓度变化为特征的平均血浆美金刚浓度分布 时间的函数(dC / dT)小于在美金刚给药后0小时至6小时之间的时间段内由相同量的美金刚立即释放形式提供的dC / dT的50%,其中 在单次剂量人体PK研究中测量dC / dT。 提供了使用该组合物治疗痴呆,特别是阿尔茨海默氏病的方法。